Key result
This editorial highlights registry analyses showing low body weight increases cardiac mortality in acute heart failure and beta-blockers improve survival in ACS with mid-range ejection fraction.
This editorial highlights international contributions to acute heart failure research, emphasizing the obesity paradox and the benefit of beta-blockers in mid-range ejection fraction.
Patients admitted with acute heart failure have a poor prognosis with a high risk of readmission and death after hospital discharge.1-4 This issue is focusing on this life-threatening condition with world-wide contributions spanning from the far East to the far West. Obesity is a significant risk factor for the development of heart failure, but on the other hand, is associated with a survival benefit in patients with established heart failure, known as the obesity paradox. An analysis from the ATTEND registry performed in Japan shows that low body weight is associated with a markedly increased cardiac mortality in acute heart failure patients.5 The impact of body weight on mortality differed on heart failure etiology and the presence of hypertension, chronic obstructive pulmonary disease, and hyponatremia. From a national registry in Portugal, we learn that patients hospitalized with an acute coronary syndrome and a mid-range ejection fraction (40-49%) represent an intermediate risk group in which beta-blocker treatment results in an in-hospital survival benefit.6
No takes yet. Share an insight, caveat, or question.
Christiaan Vrints (2019) conducted an editorial in Acute heart failure. This editorial highlights registry analyses showing low body weight increases cardiac mortality in acute heart failure and beta-blockers improve survival in ACS with mid-range ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: